Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Micron Technology, Inc. (MU) Price & Performance

AbCellera Biologics IncTrade
Micron Technology, Inc.Trade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Micron Technology, Inc. — how do they compare? AbCellera Biologics Inc trades at $10.03 (market cap $2.99B), while Micron Technology, Inc. trades at $928.27 (market cap $980.90B). The key difference: Micron Technology, Inc. is far larger — about 328.1× AbCellera Biologics Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLMU
Market Cap
$2.99B$980.90B
Sector
HealthTechnology
52-Week High
$9.76$1.21K
52-Week Low
$2.78$115.79
Enterprise Value
$2.58B$961.25B
Dividend Yield
0.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

Micron Technology, Inc.

Micron Technology (MU) trades at $925.24, up 7.46% with strong earnings momentum after beating Q1 2026 EPS estimates of $20.98 with $25.11. The stock shows bearish technical signals despite robust fundamentals including 55.91% net margin and 32.62% ROE. Recent news highlights AI-driven memory demand growth but concerns about cyclicality and competitive threats from new entrants like SpaceX's Terrafab facility.

Outlook remains positive with 81% analyst buy ratings and $1,540 consensus price target, though technical weakness and memory market cyclicality pose near-term risks. The company's strategic customer agreements provide revenue visibility through 2030, supporting long-term growth potential despite current bearish technical indicators.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Micron Technology, Inc.

Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.

Read more on MU